SNSE
NASDAQSensei Biotherapeutics Inc.
News · 26 weeks67+35%
2025-12-282026-06-21
Mix5490d
- SEC Filings24(44%)
- Insider16(30%)
- Other9(17%)
- Analyst4(7%)
- M&A1(2%)
Latest news
25 items- SECSEC Form 8-K filed by Sensei Biotherapeutics Inc.8-K - Faeth Therapeutics, Inc. (0001829802) (Filer)
- SECSEC Form S-3ASR filed by Sensei Biotherapeutics Inc.S-3ASR - Faeth Therapeutics, Inc. (0001829802) (Filer)
- INSIDERSEC Form 4 filed by Director Ramasastry Saira4 - Sensei Biotherapeutics, Inc. (0001829802) (Issuer)
- INSIDERPresident and CEO Parikh Anand Kiran converted options into 761,428 shares (SEC Form 4)4 - Sensei Biotherapeutics, Inc. (0001829802) (Issuer)
- INSIDERSEC Form 3 filed by new insider Ramasastry Saira3 - Sensei Biotherapeutics, Inc. (0001829802) (Issuer)
- INSIDERDirector Hahn Stephen M. converted options into 44,763 shares (SEC Form 4)4 - Sensei Biotherapeutics, Inc. (0001829802) (Issuer)
- INSIDERSEC Form 3 filed by new insider Hahn Stephen M.3 - Sensei Biotherapeutics, Inc. (0001829802) (Issuer)
- INSIDERAmendment: SEC Form 4 filed by President and CEO Parikh Anand Kiran4/A - Sensei Biotherapeutics, Inc. (0001829802) (Issuer)
- SECSensei Biotherapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Sensei Biotherapeutics, Inc. (0001829802) (Filer)
- PRSensei Biotherapeutics Announces Name Change to Faeth Therapeutics, Focused on Advancing PIKTOR, an Oral Therapy Targeting One of the Most Frequently Altered Pathways in Cancer— Stockholders approved conversion of the Series B preferred stock issued in the February 2026 acquisition of Faeth Therapeutics and concurrent private placement — — Company changed name to Faeth Therapeutics, Inc. on June 15, 2026; common stock expected to begin trading under the ticker symbol "FTH" on June 16, 2026 — — Anand Parikh, Faeth co-founder, appointed Chairman, President and Chief Executive Officer; Brian Stephenson, Ph.D., CFA appointed Chief Financial Officer; board strengthened with the addition of former FDA Commissioner Stephen M. Hahn, M.D., and Saira Ramasastry — — PIKTOR, an investigational all-oral multi-node inhibitor of the PI3K/AKT/mTOR pathway, on track for top
- SECSEC Form EFFECT filed by Sensei Biotherapeutics Inc.EFFECT - Sensei Biotherapeutics, Inc. (0001829802) (Filer)
- INSIDERSEC Form 4 filed by President & PEO Gerry Christopher4 - Sensei Biotherapeutics, Inc. (0001829802) (Issuer)
- INSIDERSEC Form 4 filed by Director Donenberg Phillip B.4 - Sensei Biotherapeutics, Inc. (0001829802) (Issuer)
- INSIDERSEC Form 4 filed by Director Holmen Bob4 - Sensei Biotherapeutics, Inc. (0001829802) (Issuer)
- ANALYSTBTIG Research initiated coverage on Sensei Biotherapeutics with a new price targetBTIG Research initiated coverage of Sensei Biotherapeutics with a rating of Buy and set a new price target of $55.00
- SECAmendment: SEC Form S-3/A filed by Sensei Biotherapeutics Inc.S-3/A - Sensei Biotherapeutics, Inc. (0001829802) (Filer)
- SECSEC Form 8-K filed by Sensei Biotherapeutics Inc.8-K - Sensei Biotherapeutics, Inc. (0001829802) (Filer)
- PRSensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) today announced that, effective on June 1, 2026, the Compensation Committee of Sensei's Board of Directors granted three new employees options to purchase an aggregate of 19,300 shares of the Company's common stock in connection with their employment (collectively, the "Option Awards"). The Option Awards were granted pursuant to the Company's 2026 Inducement Plan as a material inducement to the individuals entering employment with Sensei in accordance with Nasdaq Listing Rule 5635(c)(4). The Option Awards have an exercise price of $19.79, which is equal to the closing price of Sensei's common stock on June 1, 2026, and will vest, with respect to
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Sensei Biotherapeutics Inc.SCHEDULE 13G/A - Sensei Biotherapeutics, Inc. (0001829802) (Subject)
- SECAmendment: SEC Form 10-K/A filed by Sensei Biotherapeutics Inc.10-K/A - Sensei Biotherapeutics, Inc. (0001829802) (Filer)
- SECAmendment: SEC Form S-3/A filed by Sensei Biotherapeutics Inc.S-3/A - Sensei Biotherapeutics, Inc. (0001829802) (Filer)
- INSIDERLarge owner Cambrian Biopharma Inc sold $500,543 worth of shares (25,000 units at $20.02), decreasing direct ownership by 16% to 130,142 units (SEC Form 4)4 - Sensei Biotherapeutics, Inc. (0001829802) (Issuer)
- INSIDERLarge owner Peyer James sold $500,543 worth of shares (25,000 units at $20.02), decreasing direct ownership by 16% to 130,142 units (SEC Form 4)4 - Sensei Biotherapeutics, Inc. (0001829802) (Issuer)
- ANALYSTCantor Fitzgerald initiated coverage on Sensei BiotherapeuticsCantor Fitzgerald initiated coverage of Sensei Biotherapeutics with a rating of Overweight
- SECSEC Form DEFA14A filed by Sensei Biotherapeutics Inc.DEFA14A - Sensei Biotherapeutics, Inc. (0001829802) (Filer)
SNSE FAQ
7 questionsWhat does Sensei Biotherapeutics Inc. do?
Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company, engages in the discovery and development of therapies with an initial focus on treatments for cancer. The company develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune response. It is engineering ImmunoPhage product candidates to directly target antigen presenting cells and modulate the tumor microenvironment through the targeted use of nanobodies which further enhances therapeutic activity. Sensei...Where does SNSE stock trade?
Sensei Biotherapeutics Inc. (SNSE) is listed on NASDAQ.What sector and industry is SNSE in?
Sensei Biotherapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Sensei Biotherapeutics Inc. go public?
Sensei Biotherapeutics Inc. (SNSE) completed its IPO in 2021.What are analysts saying about SNSE?
Sensei Biotherapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from BTIG Research: Buy on 2026-06-11. Recent price targets range from $500.00 to $1200.00.What companies are similar to SNSE?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare SNSE side-by-side with any of them on Quantisnow.How can I track SNSE on Quantisnow?
Quantisnow aggregates Sensei Biotherapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SNSE to receive live email and push alerts on every new disclosure.